US5331014A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Effect of N,N,N-trimethylsphingosine on protein kinase-C activity; melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation
Assignee: Otsuka America Pharmaceutical Inc
•
Filing: 1991-12-23
•
Granted: 1994-07-19
•
Expires: 2011-12-23
Abstract
Abstract PCT No. PCT/US91/09196 Sec. 371 Date Jun. 30, 1993 Sec. 102(e) Date Jun. 30, 1993 PCT Filed Dec. 23, 1991 PCT Pub. No. WO92/12119 PCT Pub. Date Jul. 23, 1992.The invention relates to a novel compound, compositions and medicaments thereof and a method of inhibiting cell proliferation, platelet aggregation (induced by various factors) and inhibiting malignant phenotypes of tumor cells such as those having a metastatic property, and modulating cell adhesion molecule expression and function using said compound, composition or medicament. N,N,N-trimethylsphingosine shows superior cell proliferation inhibitory and anti-metastatic activity over related compounds.
Inventors
- 👤 Satoshi Kimura
- 👤 Yasuyuki Igarashi
- 👤 Sen-itiroh Hakomori
- 👤 Mohammad N. Ahmad
- 👤 Hirofumi Okoshi
- 👤 Kazuko Handa
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 13:57
CPC Classifications
C; C07; C07C; C07C215/00; C07C215/02; C07C215/40; A; A61; A61P; A61P29/00; A61P35/00; A61P37/00; A61P43/00; A61P7/00; A61P7/02
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
31 words
A therapeutic method for moderating inflammatory reactions comprising administering to a host in need of treatment an amount of N,N,N-trimethylsphingosine, or a pharmaceutically acceptable salt thereof, capable of inhibiting neutrophil activity.
Claim 2
Dependent Claim
31 words
A therapeutic method for moderating inflammatory reactions comprising administering to a host in need of treatment an amount of N,N,N-trimethylsphingosine, or a pharmaceutically acceptable salt thereof, capable of inhibiting neutrophil activity.
Claim 3
Dependent Claim
15 words
The method of claim 1 wherein said amount is capable of inhibiting neutrophil transendothelium migration.
Claim 4
Dependent Claim
15 words
The method of claim 1, wherein said amount is capable of inhibiting neutrophil superoxide production.
Claim 5
Dependent Claim
36 words
A therapeutic method for minimizing tissue damage resulting from superoxide exposure comprising administering to a host in need of treatment an amount of N,N,N-trimethylsphingosine, or a pharmaceutically acceptable salt thereof, capable of inhibiting neutrophil superoxide production.
Claim 6
Dependent Claim
36 words
A therapeutic method for minimizing tissue damage resulting from superoxide exposure comprising administering to a host in need of treatment an amount of N,N,N-trimethylsphingosine, or a pharmaceutically acceptable salt thereof, capable of inhibiting neutrophil superoxide production.
Claim 7
Independent Claim
16 words
A method for controlling neutrophil metabolism comprising exposing neutrophilis to an activity inhibiting amount of N,N,N-trimethylsphingosine.
Claim 8
Independent Claim
16 words
A method for controlling neutrophil metabolism comprising exposing neutrophilis to an activity inhibiting amount of N,N,N-trimethylsphingosine.
Claim 9
Dependent Claim
12 words
The method of claim 5 wherein said amount inhibits neutrophil superoxide production.
Claim 10
Dependent Claim
11 words
The method of claim 5 wherein said amount inhibits neutrophil migration.
Claim 11
Independent Claim
18 words
A method of storing biologic material comprising exposing said material to a cell growth inhibiting amount of N,N,N-trimethylsphingosine.
Claim 12
Independent Claim
18 words
A method of storing biologic material comprising exposing said material to a cell growth inhibiting amount of N,N,N-trimethylsphingosine.
Claim 13
Dependent Claim
15 words
The method of claim 8 wherein said biologic material is blood or a blood product.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-07-18 | 1998-01-17 | 1998-07-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-07-18 | 2002-01-17 | 2002-07-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-07-18 | 2006-01-17 | 2006-07-19 | $7700.00 | Window Closed / Lapsed |